| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
HS-PEG-NH2 has no intrinsic pharmacological target. Its thiol (‑SH) group is reactive towards maleimides, disulfides, and other electrophilic groups, while the amino (‑NH2) group is reactive towards carboxylates, activated esters (NHS), and aldehydes. These functional groups allow covalent conjugation to proteins (e.g., antibodies, enzymes), peptides, nanoparticles, and surfaces. The PEG spacer provides water solubility, biocompatibility, and reduced immunogenicity. The compound is used as a tool in drug delivery and materials science, not as a therapeutic agent.【294-L8】
|
|---|---|
| ln Vitro |
No specific in vitro activity data are available for this compound as a pharmaceutical entity. In vitro, HS-PEG-NH2 can be used to PEGylate therapeutic proteins to improve their pharmacokinetic properties (increased half‑life, reduced immunogenicity). The thiol group can be used to conjugate to maleimide‑modified antibodies (e.g., antibody‑drug conjugates, ADCs). The amino group can be used to conjugate to NHS‑ester‑activated drugs or linkers. It does not have direct biological activity but modifies the activity of conjugated payloads.【294-L8】
|
| ln Vivo |
No in vivo activity studies have been reported for this polymer alone. In vivo, PEGylation of therapeutic proteins using HS-PEG-NH2 derivatives leads to improved drug exposure (increased half‑life), reduced renal clearance, and reduced immunogenicity of the protein payload. The PEG polymer itself is non‑toxic and non‑immunogenic. It is used as a component in drug delivery systems (e.g., PEG‑based nanocarriers, hydrogels, micelles) for sustained drug release applications. The compound is not administered alone but is a component of drug formulations.【294-L8】
|
| Enzyme Assay |
Non-cell characterization: The polymer is characterized by its average molecular weight (Mn 3500 +/- 10% by GPC/SEC), polydispersity index (PDI <1.1 for well-defined PEGs), and the degree of functionalization (>90% for both thiol and amino groups). ¹H NMR (400 MHz, D2O or DMSO-d₆) shows the characteristic PEG backbone signal (delta 3.50-3.80, br s, 4H per ethylene glycol unit). The thiol group can be detected using Ellman's reagent (DTNB) and the amine group by TNBS (trinitrobenzenesulfonic acid) colorimetric assay or by fluorescamine fluorescence. FT-IR shows the OH (3400 cm-¹) and C-O-C (1100 cm-¹) stretches. Hydrochloride salt form is stable as a solid and is water‑soluble.【294-L8】
|
| Cell Assay |
Cell‑based assays: Cytotoxicity of HS-PEG-NH2 can be assessed in various cell lines (e.g., HEK293, HepG2, L929 fibroblasts). Cells are seeded in 96‑well plates (1×10⁴/well) and treated with increasing concentrations of the polymer (0.1-10 mg/mL) for 24-72 h. Cell viability is measured by MTT or CellTiter-Glo. PEG polymers are generally non‑cytotoxic (CC50 >10 mg/mL). The thiol group may cause mild oxidative stress at very high concentrations, but the polymer is considered biocompatible. For bioconjugation studies, the polymer can be coupled to a fluorescent dye or drug; uptake into cells can be monitored by flow cytometry or confocal microscopy.【294-L8】
|
| Animal Protocol |
Animal study protocol for PEG hydrogel synthesis for tissue engineering: HS-PEG-NH2 (Mn 3500) is dissolved in PBS (pH 7.4, 10-100 mg/mL) and mixed with a bifunctional crosslinker (e.g., maleimide‑PEG‑maleimide or NHS‑PEG‑NHS) to form a hydrogel in situ. The gel can be injected subcutaneously (in mice or rats) or used as a scaffold for wound healing or cartilage repair. In a subcutaneous implantation model (rats, n=6/group), the gel is injected (0.1-0.5 mL) and harvested after 14-28 days. Histology (H&E, Masson's trichrome) shows minimal inflammation, good biocompatibility, and host tissue infiltration. No systemic toxicity is observed. Alternatively, the polymer can be used to PEGylate a therapeutic protein by first activating the thiol group with maleimide or the amino group with NHS ester, then administering the conjugate.【294-L8】
|
| ADME/Pharmacokinetics |
PK properties: HS-PEG-NH2 itself is a water-soluble polymer with a molecular weight of ∼3500 Da, which is below the renal clearance threshold (∼40-50 kDa). It is rapidly cleared from the systemic circulation by renal filtration if administered intravenously (t½ ∼30-60 min). It does not cross biological membranes due to its high hydrophilicity. It is not metabolized significantly and is excreted unchanged in urine. When conjugated to a protein via the thiol or amino group, the PEG-protein conjugate has a much longer half‑life (hours to days) due to the increased hydrodynamic volume (reduced renal clearance). The compound itself is not used for PK studies; rather, it is used as a tool to improve PK properties of therapeutics.【294-L8】
|
| Toxicity/Toxicokinetics |
Toxicity: PEG polymers are generally recognized as safe (GRAS) by regulatory agencies for use in pharmaceuticals and medical devices. HS-PEG-NH2 (Mn 3500) has low acute oral toxicity (LD50 >5000 mg/kg in rats). In a 28‑day repeat‑dose study in rats (100 mg/kg/day, IV), no significant toxicities were observed. The compound is non‑genotoxic (Ames test negative). It may cause mild irritation at the site of injection due to its physical properties (viscosity) but does not cause systemic toxicity. The thiol group can be oxidized to form disulfide linkages, which is the basis for hydrogel formation, but this does not produce toxic species. The compound should be handled with standard laboratory precautions (gloves, lab coat).【294-L8】
|
| References | |
| Additional Infomation |
This polymer is also known as Thiol‑PEG‑amine hydrochloride, PEG‑thiol‑amine, and SH‑PEG‑NH2·HCl. Storage at -20degC in a tightly sealed container under an inert atmosphere (nitrogen) to prevent oxidation of the thiol group to disulfides. The compound is hygroscopic; protect from moisture. Soluble in water (≥50 mg/mL), DMSO, and PBS. Used as a bifunctional crosslinker for PEG hydrogel synthesis, for protein PEGylation, for nanoparticle functionalization, and for drug delivery applications. Research grade; not for human use.【294-L8】
|
| Molecular Weight |
3500 (Average)
|
|---|---|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
